ASX - By Stock
|
NOX |
Re:
Ann: 2021 AGM Letter to Shareholders and Proxy
|
|
RBx
|
26 |
6.1K |
9 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
26
|
6.1K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Ann: 2021 AGM Letter to Shareholders and Proxy
|
|
RBx
|
26 |
6.1K |
2 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
26
|
6.1K
|
2
|
|
ASX - By Stock
|
NOX |
Chemotherapy patent allowed in Europe
|
|
RBx
|
5 |
1.9K |
25 |
09/10/21 |
09/10/21 |
ASX - By Stock
|
5
|
1.9K
|
25
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
RBx
|
15 |
5.1K |
7 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
RBx
|
15 |
5.1K |
9 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
RBx
|
15 |
5.1K |
4 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
4
|
|
ASX - By Stock
|
NOX |
Impact of COVID-19 on clinical trials
|
|
RBx
|
15 |
5.1K |
17 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
17
|
|
ASX - By Stock
|
NOX |
Re:
Radiotherapy Improvements ALLOWED
|
|
RBx
|
25 |
6.6K |
14 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
25
|
6.6K
|
14
|
|
ASX - By Stock
|
NOX |
Radiotherapy Improvements ALLOWED
|
|
RBx
|
25 |
6.6K |
20 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
25
|
6.6K
|
20
|
|
ASX - By Stock
|
NOX |
Situation Report
|
|
RBx
|
5 |
1.9K |
30 |
14/09/21 |
14/09/21 |
ASX - By Stock
|
5
|
1.9K
|
30
|
|
ASX - By Stock
|
NOX |
IONIC
|
|
RBx
|
14 |
4.6K |
10 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
14
|
4.6K
|
10
|
|
ASX - By Stock
|
NOX |
A message to trolls
|
|
RBx
|
12 |
3.7K |
26 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
12
|
3.7K
|
26
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pre-clinical Data Supports a Role for Veyonda in COVID-19
|
|
RBx
|
12 |
4.6K |
6 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
12
|
4.6K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
RBx
|
49 |
14K |
4 |
25/08/21 |
25/08/21 |
ASX - By Stock
|
49
|
14K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
RBx
|
49 |
14K |
20 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
20
|
|
ASX - By Stock
|
NOX |
Wonder Drug
|
|
RBx
|
29 |
7.4K |
24 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
29
|
7.4K
|
24
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
RBx
|
71 |
22K |
11 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
71
|
22K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
RBx
|
71 |
22K |
10 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
71
|
22K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
NOX Website Refurbished
|
|
RBx
|
8 |
2.8K |
10 |
18/08/21 |
18/08/21 |
ASX - By Stock
|
8
|
2.8K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Additional Information on US NCI Collaboration
|
|
RBx
|
3 |
1.2K |
12 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
3
|
1.2K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
RBx
|
24 |
6.4K |
6 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.4K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
RBx
|
24 |
6.4K |
12 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.4K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
RBx
|
24 |
6.4K |
12 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.4K
|
12
|
|
ASX - By Stock
|
NYR |
HETEROCYCLIC INHIBITORS OF PCSK9
|
|
RBx
|
1 |
620 |
17 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
1
|
620
|
17
|
|
ASX - By Stock
|
NOX |
Re:
Grant of PK Patent is intended
|
|
RBx
|
10 |
3.7K |
16 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
10
|
3.7K
|
16
|
|
ASX - By Stock
|
NOX |
Grant of PK Patent is intended
|
|
RBx
|
10 |
3.7K |
13 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
10
|
3.7K
|
13
|
|
ASX - By Stock
|
NOX |
Phew!
|
|
RBx
|
5 |
2.3K |
16 |
16/07/21 |
16/07/21 |
ASX - By Stock
|
5
|
2.3K
|
16
|
|
ASX - By Stock
|
NOX |
Broker Webinar
|
|
RBx
|
7 |
2.5K |
9 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
7
|
2.5K
|
9
|
|
ASX - By Stock
|
NOX |
Hidden Gems
|
|
RBx
|
0 |
394 |
16 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
0
|
394
|
16
|
|
ASX - By Stock
|
NYR |
Re:
Ann: NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
|
|
RBx
|
72 |
21K |
8 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
72
|
21K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Corporate Presentation
|
|
RBx
|
7 |
2.7K |
18 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
7
|
2.7K
|
18
|
|
ASX - By Stock
|
NOX |
Chemotherapy Improvements
|
|
RBx
|
0 |
430 |
10 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
0
|
430
|
10
|
|
ASX - By Stock
|
NOX |
Targeted Drug Delivery
|
|
RBx
|
1 |
667 |
13 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
1
|
667
|
13
|
|
ASX - By Stock
|
NYR |
Re:
PCSK9 Patent
|
|
RBx
|
9 |
2.6K |
4 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
9
|
2.6K
|
4
|
|
ASX - By Stock
|
NOX |
Patent Grant
|
|
RBx
|
46 |
13K |
18 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
46
|
13K
|
18
|
|
ASX - By Stock
|
NOX |
The boy who cried wolf
|
|
RBx
|
13 |
4.8K |
23 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
13
|
4.8K
|
23
|
|
ASX - By Stock
|
NOX |
DARRT-2
|
|
RBx
|
15 |
3.8K |
17 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
15
|
3.8K
|
17
|
|
ASX - By Stock
|
NOX |
Patent facts
|
|
RBx
|
4 |
1.4K |
5 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
4
|
1.4K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Lu-PSMA data
|
|
RBx
|
6 |
1.8K |
6 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
6
|
1.8K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Perspective
|
|
RBx
|
5 |
1.5K |
5 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
5
|
1.5K
|
5
|
|
ASX - By Stock
|
NOX |
Lu-PSMA data
|
|
RBx
|
6 |
1.8K |
10 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
6
|
1.8K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Patent update
|
|
RBx
|
24 |
8.3K |
10 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
24
|
8.3K
|
10
|
|
ASX - By Stock
|
NOX |
Patent update
|
|
RBx
|
24 |
8.3K |
19 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
24
|
8.3K
|
19
|
|
ASX - By Stock
|
NOX |
Perspective
|
|
RBx
|
5 |
1.5K |
20 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
5
|
1.5K
|
20
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
RBx
|
41 |
13K |
12 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
RBx
|
41 |
13K |
11 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
RBx
|
41 |
13K |
20 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
20
|
|
ASX - By Stock
|
NYR |
PCSK9 Patent
|
|
RBx
|
9 |
2.6K |
4 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
9
|
2.6K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
RBx
|
23 |
9.9K |
12 |
18/05/21 |
18/05/21 |
ASX - By Stock
|
23
|
9.9K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
RBx
|
23 |
9.9K |
16 |
18/05/21 |
18/05/21 |
ASX - By Stock
|
23
|
9.9K
|
16
|
|